BioDelivery Sciences International (NASDAQ:BDSI) issued its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03, Fidelity Earnings reports. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. The company had revenue of $19.77 million during the quarter, compared to analysts’ expectations of $19.60 million.
NASDAQ:BDSI opened at $4.90 on Wednesday. The stock has a market cap of $350.85 million, a price-to-earnings ratio of -6.71 and a beta of 0.41. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. BioDelivery Sciences International has a fifty-two week low of $1.70 and a fifty-two week high of $5.37.
A number of analysts have weighed in on the stock. Cantor Fitzgerald set a $8.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Friday, April 26th. BidaskClub lowered shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. SunTrust Banks assumed coverage on shares of BioDelivery Sciences International in a research note on Tuesday, March 19th. They set a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of BioDelivery Sciences International in a research note on Friday, March 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $5.79.
An institutional investor recently raised its position in BioDelivery Sciences International stock. Geode Capital Management LLC lifted its stake in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 517,620 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,628 shares during the quarter. Geode Capital Management LLC owned 0.73% of BioDelivery Sciences International worth $1,915,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 56.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/08/biodelivery-sciences-international-bdsi-announces-earnings-results-beats-estimates-by-0-03-eps.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.